Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations

M. Takahashi, N. Asai, T. Iwashita, H. Murakami, Shinji Ito

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Biological and biochemical effects of multiple endocrine neoplasia type 2A (MEN-2A), type 2B (MEN-2B) and familial medullary thyroid carcinoma (FMTC) mutations on Ret function were investigated by transfection of NIH 3T3 cells. All mutations examined conferred transforming activity on Ret at variable levels. Cysteine mutations detected in MEN-2A and FMTC induced disulphide- linked homodimers of Pet on the cell surface, leading to activation of its intrinsic tyrosine kinase. Of these cysteine-mutated proteins, Ret with a codon 634 mutation had the highest transforming activity. The activity of Ret with a codon 609, 611, 618 or 620 mutation was approximately three- to five- fold lower than that of Ret with a codon 634 mutation. The first four mutations impaired the Ret cell surface expression or its correct maturation, resulting in the low transforming activity. On the other hand, the MEN-2B mutation appeared to activate Ret by an intramolecular mechanism without dimerization. In addition, we investigated the role of tyrosines present in the intracellular domain for the transforming activity of the mutant Ret proteins. As a result, we found that tyrosine 905 is essential for the transforming activity of the MEN-2A-Ret mutant protein whereas tyrosines 864 and 952 are critical for that of the MEN-2B-Ret mutant protein. Moreover, it turned out that tyrosine 1062 regulates the activity of both MEN-2A-Ret and MEN-2B-Ret and represents a binding site for the Shc adaptor protein.

Original languageEnglish
Pages (from-to)509-513
Number of pages5
JournalJournal of Internal Medicine
Volume243
Issue number6
Publication statusPublished - 16-07-1998

Fingerprint

Multiple Endocrine Neoplasia
Multiple Endocrine Neoplasia Type 2a
Mutation
Multiple Endocrine Neoplasia Type 2b
Tyrosine
Mutant Proteins
Codon
Cysteine
Shc Signaling Adaptor Proteins
NIH 3T3 Cells
Pets
Dimerization
Disulfides
Protein-Tyrosine Kinases
Transfection
Binding Sites

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Takahashi, M. ; Asai, N. ; Iwashita, T. ; Murakami, H. ; Ito, Shinji. / Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. In: Journal of Internal Medicine. 1998 ; Vol. 243, No. 6. pp. 509-513.
@article{cea7cc2f7b044c38bb2caf9ce97b529c,
title = "Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations",
abstract = "Biological and biochemical effects of multiple endocrine neoplasia type 2A (MEN-2A), type 2B (MEN-2B) and familial medullary thyroid carcinoma (FMTC) mutations on Ret function were investigated by transfection of NIH 3T3 cells. All mutations examined conferred transforming activity on Ret at variable levels. Cysteine mutations detected in MEN-2A and FMTC induced disulphide- linked homodimers of Pet on the cell surface, leading to activation of its intrinsic tyrosine kinase. Of these cysteine-mutated proteins, Ret with a codon 634 mutation had the highest transforming activity. The activity of Ret with a codon 609, 611, 618 or 620 mutation was approximately three- to five- fold lower than that of Ret with a codon 634 mutation. The first four mutations impaired the Ret cell surface expression or its correct maturation, resulting in the low transforming activity. On the other hand, the MEN-2B mutation appeared to activate Ret by an intramolecular mechanism without dimerization. In addition, we investigated the role of tyrosines present in the intracellular domain for the transforming activity of the mutant Ret proteins. As a result, we found that tyrosine 905 is essential for the transforming activity of the MEN-2A-Ret mutant protein whereas tyrosines 864 and 952 are critical for that of the MEN-2B-Ret mutant protein. Moreover, it turned out that tyrosine 1062 regulates the activity of both MEN-2A-Ret and MEN-2B-Ret and represents a binding site for the Shc adaptor protein.",
author = "M. Takahashi and N. Asai and T. Iwashita and H. Murakami and Shinji Ito",
year = "1998",
month = "7",
day = "16",
language = "English",
volume = "243",
pages = "509--513",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "6",

}

Takahashi, M, Asai, N, Iwashita, T, Murakami, H & Ito, S 1998, 'Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations', Journal of Internal Medicine, vol. 243, no. 6, pp. 509-513.

Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. / Takahashi, M.; Asai, N.; Iwashita, T.; Murakami, H.; Ito, Shinji.

In: Journal of Internal Medicine, Vol. 243, No. 6, 16.07.1998, p. 509-513.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations

AU - Takahashi, M.

AU - Asai, N.

AU - Iwashita, T.

AU - Murakami, H.

AU - Ito, Shinji

PY - 1998/7/16

Y1 - 1998/7/16

N2 - Biological and biochemical effects of multiple endocrine neoplasia type 2A (MEN-2A), type 2B (MEN-2B) and familial medullary thyroid carcinoma (FMTC) mutations on Ret function were investigated by transfection of NIH 3T3 cells. All mutations examined conferred transforming activity on Ret at variable levels. Cysteine mutations detected in MEN-2A and FMTC induced disulphide- linked homodimers of Pet on the cell surface, leading to activation of its intrinsic tyrosine kinase. Of these cysteine-mutated proteins, Ret with a codon 634 mutation had the highest transforming activity. The activity of Ret with a codon 609, 611, 618 or 620 mutation was approximately three- to five- fold lower than that of Ret with a codon 634 mutation. The first four mutations impaired the Ret cell surface expression or its correct maturation, resulting in the low transforming activity. On the other hand, the MEN-2B mutation appeared to activate Ret by an intramolecular mechanism without dimerization. In addition, we investigated the role of tyrosines present in the intracellular domain for the transforming activity of the mutant Ret proteins. As a result, we found that tyrosine 905 is essential for the transforming activity of the MEN-2A-Ret mutant protein whereas tyrosines 864 and 952 are critical for that of the MEN-2B-Ret mutant protein. Moreover, it turned out that tyrosine 1062 regulates the activity of both MEN-2A-Ret and MEN-2B-Ret and represents a binding site for the Shc adaptor protein.

AB - Biological and biochemical effects of multiple endocrine neoplasia type 2A (MEN-2A), type 2B (MEN-2B) and familial medullary thyroid carcinoma (FMTC) mutations on Ret function were investigated by transfection of NIH 3T3 cells. All mutations examined conferred transforming activity on Ret at variable levels. Cysteine mutations detected in MEN-2A and FMTC induced disulphide- linked homodimers of Pet on the cell surface, leading to activation of its intrinsic tyrosine kinase. Of these cysteine-mutated proteins, Ret with a codon 634 mutation had the highest transforming activity. The activity of Ret with a codon 609, 611, 618 or 620 mutation was approximately three- to five- fold lower than that of Ret with a codon 634 mutation. The first four mutations impaired the Ret cell surface expression or its correct maturation, resulting in the low transforming activity. On the other hand, the MEN-2B mutation appeared to activate Ret by an intramolecular mechanism without dimerization. In addition, we investigated the role of tyrosines present in the intracellular domain for the transforming activity of the mutant Ret proteins. As a result, we found that tyrosine 905 is essential for the transforming activity of the MEN-2A-Ret mutant protein whereas tyrosines 864 and 952 are critical for that of the MEN-2B-Ret mutant protein. Moreover, it turned out that tyrosine 1062 regulates the activity of both MEN-2A-Ret and MEN-2B-Ret and represents a binding site for the Shc adaptor protein.

UR - http://www.scopus.com/inward/record.url?scp=0031808878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031808878&partnerID=8YFLogxK

M3 - Article

VL - 243

SP - 509

EP - 513

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 6

ER -